Activity of fosfomycin against extended-spectrum-β-lactamase-producing uropathogens in patients in the community and hospitalized patients

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 2, 2016, Pages 1134-1136

  Linsenmeyer, Katherine ^a,b   Strymish, Judith ^a,c   Weir, Susan ^a,b   Berg, Gretchen ^a,b   Brecher, Stephen ^a,b   Gupta, Kalpana ^a,b,d  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d VA National Center for Occupational Health and Infection Control   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; NITROFURANTOIN; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT; BETA LACTAMASE;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CITROBACTER; DRUG ACTIVITY; ENTEROBACTER; ESCHERICHIA COLI; HOSPITAL PATIENT; HUMAN; KLEBSIELLA; MALE; MORGANELLA; PREVALENCE; PRIORITY JOURNAL; PROTEUS; PSEUDOMONAS; SERRATIA; VETERAN; DRUG EFFECTS; MASSACHUSETTS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PATHOGENICITY; PUBLIC HOSPITAL; URINARY TRACT INFECTIONS;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; FOSFOMYCIN; HOSPITALS, VETERANS; HUMANS; KLEBSIELLA; MALE; MASSACHUSETTS; MICROBIAL SENSITIVITY TESTS; URINARY TRACT INFECTIONS;

EID: 84957927506     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02614-15     Document Type: Article

References (18)

1. Li B, Sun JY, Liu QZ, Han LZ, Huang XH, Ni YX. 2011. High prevalence of CTX-M β-lactamases in faecal Escherichia coli strains from healthy humans in Fuzhou, China. Scand J Infect Dis 43:170-174. http://dx.doi.org/10.3109/00365548.2010.538856.
2. Gibold L, Robin F, Tan RN, Delmas J, Bonnet R. 2014. Four-year epidemiological study of extended-spectrum β-lactamase-producing Enterobacteriaceae in a French teaching hospital. Clin Microbiol Infect 20:O20-O26. http://dx.doi.org/10.1111/1469-0691.12321.
3. Gupta K, Trautner B. 2012. In the clinic. Urinary tract infection. Ann Intern Med 156:ITC3-1-ITC3-15.
4. Bonkat G, Muller G, Braissant O, Frei R, Tschudin-Suter S, Rieken M, Wyler S, Gasser TC, Bachmann A, Widmer AF. 2013. Increasing prevalence of ciprofloxacin resistance in extended-spectrum-β-lactamase-producing Escherichia coli urinary isolates. World J Urol 31:1427-1432. http://dx.doi.org/10.1007/s00345-013-1031-5.
5. Pogue JM, Marchaim D, Abreu-Lanfranco O, Sunkara B, Mynatt RP, Zhao JJ, Bheemreddy S, Hayakawa K, Martin ET, Dhar S, Kaye KS, Lephart PR. 2013. Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant Enterococcus, Detroit, 2008-10. J Antibiot (Tokyo) 66:625-627. http://dx.doi.org/10.1038/ja.2013.56.
6. Neuner EA, Sekeres J, Hall GS, van Duin D. 2012. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrob Agents Chemother 56:5744-5748. http://dx.doi.org/10.1128/AAC.00402-12.
7. Meier S, Weber R, Zbinden R, Ruef C, Hasse B. 2011. Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection 39:333-340. http://dx.doi.org/10.1007/s15010-011-0132-6.
8. Rodriguez-Avial C, Rodriguez-Avial I, Hernandez E, Picazo JJ. 2013. Increasing prevalence of fosfomycin resistance in extended-spectrum-beta-lactamase-producing Escherichia coli urinary isolates (2005-2009-2011). Rev Esp Quimioter 26:43-46. (In Spanish.)
9. Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE, Kapaskelis A, Nikita D, Michalopoulos A. 2010. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 35:194-199. http://dx.doi.org/10.1016/j.ijantimicag.2009.10.005.
10. Hirsch EB, Tam VH. 2010. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 65:1119-1125. http://dx.doi.org/10.1093/jac/dkq108.
11. Cai Y, Wang R, Liang B, Bai N, Liu Y. 2011. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 55:1162-1172. http://dx.doi.org/10.1128/AAC.01402-10.
12. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 19th informational supplement. CLSI document M100-19. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
14. de Cueto M, Lopez L, Hernandez JR, Morillo C, Pascual A. 2006. In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures. Antimicrob Agents Chemother 50:368-370. http://dx.doi.org/10.1128/AAC.50.1.368-370.2006.
15. Waiwarawooth J, Jutiworakul K, Joraka W. 2006. The prevalence and susceptibility patterns of ESBL-producing Klebsiella pneumonia and Escherichia coli in Chonburi Hospital. J Infect Dis Antimicrob Agents 23:57-65.
16. Abdullah FEMA, Ishrad M, Rauf H, Afzal N, Rasheed A. 2013. Current efficacy of antibiotics against Klebsiella isolates from urine samples-a multi-centric experience in Karachi. Pak J Pharm Sci 26:11-15.
17. Tharavichitkul P, Khantawa B, Bousoung V, Boonchoo M. 2005. Activity of fosfomycin against extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli in Maharaj Nakorn Chiang Mai Hospital. J Infect Dis Antimicrob Agents 22:121-126.
18. Pitout JD, Laupland KB. 2008. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 8:159-166. http://dx.doi.org/10.1016/S1473-3099(08)70041-0.